Who are Ketamine and Magnesium Sulfate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Ketamine (1st phase), Sevoflurane+Nitrous oxide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketamine-and-magnesium-sulfate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ketamine and Magnesium Sulfate — Competitive Intelligence Brief

Ketamine and Magnesium Sulfate (Ketamine and Magnesium Sulfate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist combination. Area: Anesthesia, Pain Management.

marketed NMDA receptor antagonist combination NMDA receptor Anesthesia, Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ketamine and Magnesium Sulfate (Ketamine and Magnesium Sulfate) — Ain Shams University. Ketamine acts as an NMDA receptor antagonist while magnesium sulfate enhances NMDA receptor blockade and provides neuroprotection, together reducing pain and providing anesthesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketamine and Magnesium Sulfate TARGET	Ketamine and Magnesium Sulfate	Ain Shams University	marketed	NMDA receptor antagonist combination	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Ketamine (1st phase)	Ketamine (1st phase)	Shalvata Mental Health Center	marketed	NMDA receptor antagonist	NMDA receptor
Sevoflurane+Nitrous oxide	Sevoflurane+Nitrous oxide	Huazhong University of Science and Technology	marketed	General anesthetic (volatile anesthetic + inhalational anesthetic)	GABA receptors, NMDA receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist combination class)

Ain Shams University · 1 drug in this class
National Cancer Institute, Egypt · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class
University of Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketamine and Magnesium Sulfate — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-and-magnesium-sulfate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab